department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

News

when

Latest
Archive

by source

All Sources
Sources Page

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

made by humans and a good dog

home
jobs
news
search

calendar

19 catalysts · 4,686 phase readout · 2,350 8k filing · 285 earnings · 243 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

agenda month

show past →

sort

soonest latest type sponsor alpha

type: patent expiry×type: approval×type: filing×clear all

type

phase readout4,686
8k filing2,350
earnings285
pdufa243
phase 2 completion172
phase 1 completion73

phase 2 initiation

phase 1 initiation40

phase 1 2 completion35

phase 0 trial completion23

therapy area

Infectious Disease9
Ophthalmology5
Oncology2
Dermatology1
Pulmonology1

Week of Apr 20, 2026

›Apr 24, 2026patent expiry91d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata

›Apr 24, 2026patent expiry91d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

full page →lenvatinib mesylate →source: globaldata

›Apr 25, 2026patent expiry90d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

full page →SL-901 →source: globaldata

›Apr 26, 2026patent expiry89d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

full page →BB-101 →source: globaldata

Week of Apr 27, 2026

›Apr 27, 2026patent expiry88d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

full page →SB-692342 →source: globaldata

›Apr 28, 2026patent expiry

Date TBD

›TBDapprovalOZURDEX (DEXAMETHASONE) — FDA approvaldexamethasone LA

Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL

full page →dexamethasone LA →fda approvals ↗

›TBDapproval

87d ago

GSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →dolutegravir sodium →source: globaldata

›Apr 28, 2026patent expiry87d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata

›Apr 28, 2026patent expiry87d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir sodium →source: globaldata

›Apr 28, 2026patent expiry87d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir + rilpivirine LA →source: globaldata

›Apr 28, 2026patent expiry87d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir LA →source: globaldata

›Apr 30, 2026patent expiry85d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

full page →isavuconazonium sulfate →source: globaldata